TheraRadar
Data updated: May 26, 2026

IZERVAY (avacincaptad pegol sodium)

Breakthrough Therapy Priority Review Fast Track
Ophthalmology Approved 2023-08-04

IZERVAY is indicated for the treatment of Geographic Atrophy; Age-Related Macular Degeneration.

Source: FDA Label • ASTELLAS

How IZERVAY Works

Avacincaptad pegol is a PEGylated RNA aptamer that binds to and inhibits complement protein C5. By inhibiting C5, the drug prevents its cleavage into the effector molecules C5a and C5b, thereby decreasing the formation of the membrane attack complex (MAC).

2
Indications
--
Phase 3 Trials
1
Priority Reviews
2
Years on Market

Details

Status
Prescription
First Approved
2023-08-04
Patent Cliff
2034

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
INTRAVITREAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: AVACINCAPTAD PEGOL SODIUM

IZERVAY Approval History

2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2023 to 2026 · 1 indication expansions
Feb 2026 SUPPL
Label · Labeling
Feb 2025 SUPPL
Efficacy
Aug 2023 ORIGINAL Priority
New Drug · Type 1 - New Molecular Entity

What IZERVAY Treats

2 indications

IZERVAY is approved for 2 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Geographic Atrophy
  • Age-Related Macular Degeneration
Source: FDA Label

IZERVAY Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to IZERVAY

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

SYFOVRE
PEGCETACOPLAN
2 shared
APELLIS PHARMS
Shared indications:
Geographic AtrophyAge-Related Macular Degeneration
VISUDYNE
VERTEPORFIN
1 shared
BAUSCH LOMB IRELAND
Shared indications:
Age-Related Macular Degeneration
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IZERVAY FDA Label Details

Indications & Usage

FDA Label (PDF)

IZERVAY is indicated for the treatment of Geographic Atrophy; Age-Related Macular Degeneration.

View full patent landscape →
6 OB patents · 3 families · 170 international docs across 31 countries

IZERVAY Patents & Exclusivity

Latest Patent: Jul 2034

Patents (6 active)

US11491176 Expires Jul 11, 2034
US11273171 Expires Jul 11, 2034
US12016875 Expires Jul 11, 2034
US9617546 Expires Feb 14, 2027
US7579456 Expires Feb 14, 2027
US8236773 Expires Nov 11, 2026
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for IZERVAY

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2034
  • 6 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 2 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.